Molecular targets and cancer therapeutics: Discovery, development and clinical validation

Drug Resistance Updates

Volumn 3, Issue 2, 2000, Pages 67-73

  Teicher, Beverly A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 6 O CYCLOHEXYLMETHYLGUANINE; 7 HYDROXYSTAUROSPORINE; CEP 701; CEP 751; COMBRETASTATIN A4; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GELDANAMYCIN; PK 1166; SQUALAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG; WHI P 97;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CONTROL; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG MECHANISM; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

EID: 0034176467     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0123     Document Type: Article

References (23)

1. Fedi P., Aaronson S. Signal transduction through tyrosine kinase growth factor receptors. Gutkind J. S., Signaling Networks and Cell Cycle Control. 2000;23-36 Humana Press Inc. Totowa, NJ.
2. Sakagami M, Morrison P, Welch WJ. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chap. 1999;4:19-28.
3. Vasilevskaya IA, O'Dwyer PJ. Effects of geldanamycin on signalling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res 1999;59:3935-3940.
4. Neckers L, Mimnaugh E, Schulte TW. Hsp90 as an anti-cancer agents. Drug Resistance Updates 1999;2: 165-172.
5. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. In: Signaling Networks and Cell Cycle Control. JS Gutkind, ed. Humana Press Inc., Totowa, NJ. 2000;455-468.
6. Sausville EA, Senderowicz AM. Chemical cyclin-dependent kinase inhibitors: therapeutic implications. In: Signaling Networks and Cell Cycle Control. JS Gutkind, ed. Humana Press Inc., Totowa, NJ. 2000;559-570.
7. Hajduch M, Havlieek L, Vesely J et al. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv Exp Med Biol 1999;457:341-353.
8. Sausville EA, Zaharevitz D, Gussio R et al. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Thera 1999;82:285-292.
9. Zaharevitz DW, Gussio R, Leost M et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 1999;59:2566-2569.
10. Kubo A, Nakagawa K, Varma RK et al. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res 1999;5:4279-4286.
11. Teicher BA, Ara G, Herbst R et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645.
12. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999;13:239-252.
13. Gil J, Yamamoto H, Zapata JM et al. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 1999;59:2034-2037.
14. Wen W, Moses MA, Wiederschain D et al. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6056.
15. Yoon SS, Eto H, Lin C-M et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251-6256.
16. Katzenstein HM, Rademaker AW, Senger C et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999;5:4273-4278.
17. Teicher BA. Role of angiogenesis in the response to anticancer therapies. Drug Resistance Updates 1998;1:59-61.
18. Blancer C, Harris AL. The molecular basis of the hypoxia response pathway: tumor hypoxia as a therapy target. Cancer Metas Rev 1998;17:187-194.
19. Maxwell PH, Wiesener MS, Chang GW et al. The tumor supressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
20. Brown JM. Hypoxic cytotoxic agents: a new approach to cancer chemotherapy. Drug Resistance Updates 2000;3(in press).
21. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev 1999;13:51-64.
22. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med 1999;50:507-529.
23. Portielje JEA, Kruit WHJ, Schuler M et al. Phase 1 study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 1999;5:3983-3989.